Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711066 | 0.92 | KDM4E (0.33) | EPHX1KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14891993 | 0.83 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3463025 | 0.81 | EPHX1 (0.38) | EPHX1PTGS2 | |
| SCHEMBL14924188 | 0.79 | USP2 (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL18256712 | 0.79 | AOC2 (0.34) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3462689 | 0.79 | KDM4E (0.43) | EPHX1KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL21798069 | 0.79 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL3462696 | 0.78 | EPHX1 (0.35) | EPHX1 | |
| SCHEMBL15108053 | 0.77 | KDM4E (0.34) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL18256646 | 0.77 | KDM4E (0.34) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118943463-A | Secondary battery, method for manufacturing the same, and electronic device | 宁德新能源科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| WO-2024211274-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | NOHMs Technologies, Inc. (US) | 2024-10-10 | — | — | WO | claimed |
| US-20240339662-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | NOHMs Technologies, Inc. (US) | 2024-10-10 | — | — | US | claimed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4303978-B1 | ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | SK ON CO LTD (KR) | 2025-01-29 | — | — | EP | disclosed |
| CN-118943463-A | Secondary battery, method for manufacturing the same, and electronic device | 宁德新能源科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024211274-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | NOHMs Technologies, Inc. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240339662-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | NOHMs Technologies, Inc. (US) | 2024-10-10 | — | — | US | disclosed |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2024-08-13 | — | — | US | disclosed |
| US-12027669-B2 | Electrolyte solution for lithium secondary battery and lithium secondary battery including the same | SK ON CO., LTD. (KR) | 2024-07-02 | — | — | US | disclosed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | disclosed |
| EP-1486501-B1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007143847-A1 | SPIROTROPANE COMPOUNDS | VIROCHEM PHARMA INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-7250429-B2 | Aminomethyl-substituted thiazolobenzimidazole compounds | ASTELLAS PHARMA INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20070088032-A1 | Processes for the Preparation of Benzoimidazole Derivatives | TOM NORMA J | 2007-04-19 | — | — | US | disclosed |
| US-7183414-B2 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183414-B2 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC (US) | 2007-02-27 | — | — | US | disclosed |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1486501-A1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | EPHX1 1521/4885KDM4E 3535/4885USP2 3645/4885 |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | GRM1, GRIN1, GRM3 | EPHX1 2482/4885KDM4E 1650/4885USP2 3686/4885 |
| US-20070088032-A1 | Processes for the Preparation of Benzoimidazole Derivatives | CCNI, CCNT1, CCNE1 | EPHX1 2392/4885KDM4E 739/4885USP2 3794/4885 |
| US-20240339662-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | SELE, CYCS, EPCAM | EPHX1 1386/4885KDM4E 249/4885USP2 3534/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | EPHX1 3073/4885KDM4E 272/4885USP2 2449/4885 |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | NQO2, NQO1, GLS | EPHX1 1826/4885KDM4E 2187/4885USP2 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.